SCHEMBL809748

SCHEMBL809748

COC(=O)C1=CCCCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 3/20 0.57
HDAC4 P56524 2/20 0.57
HDAC8 Q9BY41 2/20 0.57
HDAC6 Q9UBN7 2/20 0.57
CHRM3 P20309 2/20 0.52
LMNA P02545 1/20 0.50
CHRM2 P08172 1/20 0.50
CHRM4 P08173 1/20 0.50
CHRM5 P08912 1/20 0.50
THRB P10828 1/20 0.50
CHRM1 P11229 1/20 0.50
CTSK P43235 1/20 0.50
BLM P54132 1/20 0.49
MCOLN3 Q8TDD5 1/20 0.49
HDAC3 O15379 2/20 0.48
HDAC1 Q13547 2/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48
ALDH1A1 P00352 3/20 0.41
MAPT P10636 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14827239 0.98 HDAC4 (0.55) HDAC2HDAC4HDAC8HDAC6CHRM3
SCHEMBL15426911 0.98 HDAC4 (0.55) HDAC2HDAC4HDAC8HDAC6CHRM3
SCHEMBL15426906 0.98 HDAC4 (0.55) HDAC2HDAC4HDAC8HDAC6CHRM3
SCHEMBL11371613 0.98 HDAC4 (0.55) HDAC2HDAC4HDAC8HDAC6CHRM3
SCHEMBL11326897 0.98 HDAC4 (0.55) HDAC2HDAC4HDAC8HDAC6CHRM3
SCHEMBL4710137 0.98 HDAC4 (0.55) HDAC2HDAC4HDAC8HDAC6CHRM3
SCHEMBL11323894 0.98 HDAC4 (0.55) HDAC2HDAC4HDAC8HDAC6CHRM3
SCHEMBL9806702 0.98 HDAC4 (0.55) HDAC2HDAC4HDAC8HDAC6CHRM3
SCHEMBL9806700 0.98 HDAC4 (0.55) HDAC2HDAC4HDAC8HDAC6CHRM3
SCHEMBL11371607 0.98 HDAC4 (0.55) HDAC2HDAC4HDAC8HDAC6CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2976400-B1 ZUSAMMENSETZUNG, ENTHALTEND ALLOPHANATE VENCOREX FRANCE (FR) 2024-07-24 EP claimed
EP-4332124-A1 METHYL METHACRYLATE-CONTAINING COMPOSITION AND METHYL METHACRYLATE POLYMER PRODUCTION METHOD Mitsubishi Chemical Corporation (JP) 2024-03-06 EP claimed
US-20240059818-A1 METHYL METHACRYLATE-CONTAINING COMPOSITION AND METHYL METHACRYLATE POLYMER PRODUCTION METHOD MITSUBISHI CHEMICAL CORPORATION (JP) 2024-02-22 US claimed
CN-117242103-A Methyl methacrylate-containing composition and method for producing methyl methacrylate polymer 三菱化学株式会社 2023-12-15 CN claimed
WO-2022230913-A1 METHYL METHACRYLATE-CONTAINING COMPOSITION AND METHYL METHACRYLATE POLYMER PRODUCTION METHOD 三菱ケミカル株式会社 2022-11-03 WO claimed
CN-109761810-B Preparation method of inactive alkene aryl compound 浙江工业大学 2021-07-27 CN claimed
CN-106588525-A Method for synthesizing ph-dicarbonyl-aryl-formic-ether series compounds based on metal-free participation method 嘉兴学院 2017-04-26 CN claimed
EP-1363952-B1 METHOD FOR OBTAINING A STABILISED PHOTOCHROMIC LATEX, LATEX OBTAINED AND USE IN OPHTHALMIC OPTICS ESSILOR INT (FR) 2005-07-27 EP claimed
US-6740699-B2 EMULSION POLYMERIZATION OF CYCLOHEXENE-STABILIZED SOLUTION OF METHALLYL ALCOHOL; PHOTOSTABILITY ESSILOR INTERNATIONAL COMPAGNIE GENERALE D'OPTIQUE (FR) 2004-05-25 US claimed
US-20030100672-A1 Method for obtaining a stabilized photochromic latex, latex obtained, and application to ophthalmic optics ESSILOR INTERNATIONAL COMPAGNIE GENERALE D'OPTIQUE 2003-05-29 US claimed
WO-2025224168-A1 ARYL SULFONE AND SULFANONE DERIVATIVES AS OREXIN RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2025-10-30 WO disclosed
EP-4613784-A1 ESTER COMPOUND-CONTAINING COMPOSITION, METHOD FOR PRODUCING SAME, POLYMERIZABLE COMPOSITION, (METH)ACRYLIC POLYMER, AND METHOD FOR PRODUCING SAME Mitsubishi Chemical Corporation (JP) 2025-09-10 EP disclosed
US-20250250223-A1 ESTER COMPOUND-CONTAINING COMPOSITION, METHOD FOR PRODUCING SAME, POLYMERIZABLE COMPOSITION, (METH)ACRYLIC POLYMER, AND METHOD FOR PRODUCING SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2025-08-07 US disclosed
WO-2025124698-A1 ARYL SULFONE AND SULFANONE DERIVATIVES AS OREXIN RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2025-06-19 WO disclosed
CN-120118001-A Aerobic nitriding method for olefin compounds 北京大学 2025-06-10 CN disclosed
EP-0135142-A2 Cephalosporin derivatives and process for their preparation HOECHST AKTIENGESELLSCHAFT (DE) 1985-03-27 EP disclosed
EP-0111934-A2 Cephalosporin derivatives and process for their preparation HOECHST AKTIENGESELLSCHAFT (DE) 1984-06-27 EP disclosed
EP-0088320-A2 Cephalosporin derivatives and process for their preparation HOECHST AKTIENGESELLSCHAFT (DE) 1983-09-14 EP disclosed
EP-0064740-A2 Cephalosporin derivatives, and process for their preparation HOECHST AKTIENGESELLSCHAFT (DE) 1982-11-17 EP disclosed
US-4249015-A Preparation of organic acids and/or esters SHELL OIL COMPANY (US) 1981-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250250223-A1 ESTER COMPOUND-CONTAINING COMPOSITION, METHOD FOR PRODUCING SAME, POLYMERIZABLE COMPOSITION, (METH)ACRYLIC POLYMER, AND METHOD FOR PRODUCING SAME MMAB, ADCY8, MAT1A HDAC2 2887/4885HDAC4 3011/4885HDAC8 845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.